{"version":"1.0","provider_name":"Breakthrough T1D","provider_url":"https:\/\/breakthrought1d.eu\/nl","author_name":"ylt-admin","author_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/","title":"Hoe gaat het eraan toe bij ViaCyte? - Breakthrough T1D","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"EWEtrSMJKr\"><a href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/hoe-gaat-eraan-toe-viacyte\/\">Hoe gaat het eraan toe bij ViaCyte?<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/hoe-gaat-eraan-toe-viacyte\/embed\/#?secret=EWEtrSMJKr\" width=\"600\" height=\"338\" title=\"&#8220;Hoe gaat het eraan toe bij ViaCyte?&#8221; &#8212; Breakthrough T1D\" data-secret=\"EWEtrSMJKr\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/breakthrought1d.eu\/nl\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"ViaCyte opende vorige maand zijn deuren voor een kleine groep van Breakthrough T1D vrijwilligers en medewerkers. De groep zag hoe ViaCyte de laatste tien jaar een therapie van vervangende cellen ontwikkelt voor de behandeling van type 1 diabetes (T1D). &#8220;We hoorden hoe stamcellen functionerende alvleeskliercellen worden in het medicijnadministratiesysteem van macrocapsules van ViaCyte en hoe [&hellip;]","thumbnail_url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/viacyte-150x150-1.jpg"}